RemeGen Co., Ltd. on 14 May 2026 signed four agreements with Huatai Securities Co., Ltd. (HTSC) to deploy RMB 453.00 million of temporary idle funds into low- to-medium-risk wealth management products. The purchases form part of a previously approved mandate—granted at the Board’s 36th meeting on 27 March 2026—allowing the company to invest up to RMB 2.50 billion of self-owned funds for cash management purposes.

Transaction breakdown • RMB 60.00 million: Guoshou Asset – Yuanliu 2158 Insurance Asset Management Product (fixed-income; low-to-medium risk; open-ended). • RMB 75.00 million: Huatai Zijin Weekly Subscription 6-Month Rolling Hold Bond Initiation Fund (fixed-income; low-to-medium risk; open-ended). • RMB 102.00 million: Shengxinxiang – Huatai WEFUND Fixed Income Private FOF 1066 (fixed-income; low-to-medium risk; 10-year term with exit flexibility). • RMB 216.00 million: Shengxinxiang – Huatai WEFUND Private FOF 1068 (mixed; medium risk; 10-year term with exit flexibility).

Regulatory context Aggregated, the RMB 453.00 million commitment pushes at least one of the applicable percentage ratios above 5 % but below 25 %. Under Hong Kong Listing Rule 14.07, the series of purchases qualifies as a discloseable transaction, triggering mandatory reporting and announcement requirements.

Strategic rationale Management aims to enhance returns on surplus cash while maintaining strict risk controls. Expected yields are linked to market performance and not fixed; however, the products are projected to offer higher returns than comparable bank time deposits.

Counterparty profile HTSC is an independent PRC-based securities firm listed in both Shanghai (601688) and Hong Kong (06886), offering wealth management, institutional services, investment management and international business. RemeGen confirms that HTSC and its ultimate beneficial owners are independent third parties relative to the company and its connected persons.

Board assessment Directors regard the terms of the four HTSC agreements as fair, conducted at arm’s length and aligned with shareholder interests, citing the potential to optimise capital utilisation without materially elevating risk exposure.